Press releases
- Mahesh Krishnan Elected to Halozyme's Board of Directors
- Halozyme to Report First Quarter 2024 Financial and Operating Results
- Halozyme to Participate in Upcoming Investor Conferences
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
- Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
More ▼
Key statistics
On Thursday, Halozyme Therapeutics Inc (RV7:STU) closed at 37.10, -8.55% below its 52-week high of 40.57, set on Aug 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.51 |
---|---|
High | 37.10 |
Low | 36.51 |
Bid | 36.69 |
Offer | 37.21 |
Previous close | 35.70 |
Average volume | 4.44 |
---|---|
Shares outstanding | 127.05m |
Free float | 125.64m |
P/E (TTM) | 18.88 |
Market cap | 5.06bn USD |
EPS (TTM) | 2.11 USD |
Data delayed at least 15 minutes, as of May 02 2024.
More ▼